Consistently, Choi et al. [1] provided evidence supporting this hypothesis: PD-L1 in DRG2-depleted cancer cells showed reduced binding to recombinant PD-1 and exhibited defects in inhibiting T-cell activity. Here, DRG2 is linked to cancer.